1Pectasides D, Visvikis A,Aspropotamitis A,et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase Ⅱ trial. Eur J Cancer,2000,36:74-79.
2Dodd PM, McCaffrey JA, Hilton S, et al.Phase Ⅰ evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol, 2000, 18:
3Tanagho EA,McAninch JW. Smith' s General Urology. 15th ed. McGraw-Hill Companies, 2001. 355 -368.
4Saxman SB,Propert KJ,Einhorn LH,et al.Long-term follow-up of a Phase Ⅲ Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Cl
5Stickle M, Meyenburg W,Wellek S,et al.Advanced bladder cancer( stage pT3b, pT4a,pN1 and pN2 ): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol, 1992,148:302-306.
6Natale RB, Grossman HB, Blumenstein B, et al. Randomized phase Ⅲ trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer ( abstract 3 ). Proc Am Soc Clin Oncol,2001,20 :2.
7Sternberg CN, Parmar MK. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol,2001,19 (suppl) :21-26.
8Uygur MC,Yaman I,Altug U,et al. Conservative management of stage T2 or T3a bladder cancer with deep transurethral resection followed by four cycles of chemotherapy. Br J Urol,1996,78:201-204.
9Kuczyk M,Turkeri L,Hammerer P,et al. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol,2003,44:57-64.
10Sternberg CN,Yagoda A,Scher HI,et al.Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer, 1989,64:2448-2458.
